Cabozantinib (XL184) At 40 Mg in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC): Results of a Phase 2 Non-Randomized Expansion Cohort (NRE) von de Bono, J.S., Smith, M.R., Rathkopf, D., Corn, P.G., Mukherji, D., Harzstark, A.L., Sartor, O.A., Smith, D.C., Tunariu, N., Sweeney, C.

Volltext

51 RADIOLOGIC PROGRESSION PREDICTS OVERALL SURVIVAL IN PATIENTS (PTS) WITH ANDROGEN INDEPENDENT PROSTATE CANCER (AIPC) WHO RECEIVED FIRST LINE DOCETAXEL; AN ANALYSIS FROM THE SPARC... von Witjes, J.A, Petrylak, D, Sartor, O.A, Noursalehi, M, Sternberg, N, Wirth, M, Billiet, I, Petrone, M.E, McKeam, T.J, George, M

Volltext

SATRAPLATIN (S) INCREASES PROGRESSION-FREE SURVIVAL (PFS) AND DELAYS PAIN PROGRESSION IN PATIENTS (PTS) WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) THAT HAVE PROGRESSED AFTER PR... von Sternberg, N, Sartor, O.A, Petrylak, D.P, Witjes, F, Bodrogi, I, Harper, P, James, N, Demkov, T, Eymard, J-C, Wirth, M

Volltext

AB0210 Vitamin D and cardiovascular disease in systemic lupus erythematosus von Monticielo, O.A., Chies, J.A.B., Rucatti, G.G., Carlucci, M.S., Sartor, N.C., Souza, E.A., Rabaioli, P.S.B., Pirolli, R., Xavier, R.M., Brenol, J.C.T.

Volltext